iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596 clinical trials
Also written FT596.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- FT596
- 3
Studies by the year they started
3 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Fate Therapeutics (2) · Masonic Cancer Center, University of Minnesota (1)
Studies
Open first, then newest update. How each study uses iPSC-derived CD16/IL-15RF-expressing Anti-CD19 CAR-NK Cells FT596 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHLCompletedPhase 1Masonic Cancer Center, University of MinnesotaNCT04555811Written as FT596
- FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal AntibodiesTerminatedPhase 1Fate TherapeuticsNCT04245722Written as FT596
- FT596 in Combination With R-CHOP in Subjects With B-Cell LymphomaWithdrawnPhase 1Fate TherapeuticsNCT05934097Written as FT596